Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
Drug-associated bullous pemphigoid has been shown to follow long-term gliptin (dipeptidyl-peptidase 4 inhibitors) intake. This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary cent...
Saved in:
Main Authors: | Dana Shalmon (Author), Efrat Bar-Ilan (Author), Alon Peled (Author), Shamir Geller (Author), Jonathan Bar (Author), Naama Schwartz (Author), Eli Sprecher (Author), Mor Pavlovsky (Author) |
---|---|
Format: | Book |
Published: |
Medical Journals Sweden,
2024-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid
by: Outi Lindgren, et al.
Published: (2019) -
Gliptin-Associated Bullous Pemphigoid - A Series of 3 Cases
by: Prajesh K. Bhunya, et al.
Published: (2024) -
Recalcitrant infantile bullous pemphigoid successfully treated with cyclosporine
by: Efrat Bar-Ilan, MD, et al.
Published: (2022) -
BioNTech COVID-19 (BNT162b2) Vaccination and Varicella Zoster Reactivation: A Comprehensive Cross-sectional Study
by: Shir Azrielant, et al.
Published: (2024) -
Semi-circular Depression on the Leg Diagnosed by High-frequency Ultrasound: A Quiz
by: Eyal Taleb, et al.
Published: (2021)